| Particulars (Rupees in Crores.) | Dec-2024 | Sept-2024 | Jun-2024 | Mar-2024 | Dec-2023 |
|---|---|---|---|---|---|
Gross Sales | 3,374.28 | 3,414.67 | 3,031.82 | 2,935.82 | 3,323.87 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 3,374.28 | 3,414.67 | 3,031.82 | 2,935.82 | 3,323.87 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 92.99 | 134.48 | 120.31 | 88.17 | 93.64 |
Total Income | 3,467.27 | 3,549.15 | 3,152.13 | 3,023.99 | 3,417.51 |
Total Expenditure | 2,614.89 | 2,661.84 | 2,423.18 | 2,546.36 | 2,667.59 |
PBIDT | 852.38 | 887.31 | 728.95 | 477.63 | 749.92 |
Interest | 36.03 | 28.14 | 29.11 | 26.86 | 25.46 |
PBDT | 816.35 | 859.17 | 699.84 | 450.77 | 724.46 |
Depreciation | 85.28 | 78.91 | 80.48 | 83.43 | 69.56 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 159.04 | 155.88 | 124.43 | 83.85 | 113.6 |
Deferred Tax | -68.76 | -77.58 | -55.31 | -20.99 | -62.98 |
Reported Profit After Tax | 640.79 | 701.96 | 550.24 | 304.48 | 604.28 |
Minority Interest After NP | 14.97 | 13.32 | 5.08 | 10.92 | 9.32 |
Net Profit after Minority Interest | 625.82 | 688.64 | 545.16 | 293.56 | 594.96 |
Extra-ordinary Items | 0 | 0 | 0 | -9.66 | -42.41 |
Adjusted Profit After Extra-ordinary item | 625.82 | 688.64 | 545.16 | 303.22 | 637.37 |
EPS (Unit Curr.) | 52.34 | 57.6 | 45.6 | 24.55 | 49.76 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 1,850 | 0 | 0 | 0 | 1,750 |
Equity | 23.91 | 23.91 | 23.91 | 23.91 | 23.91 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 25.26 | 25.98 | 24.04 | 16.26 | 22.56 |
PBDTM(%) | 24.19 | 25.16 | 23.08 | 15.35 | 21.79 |
PATM(%) | 18.99 | 20.55 | 18.14 | 10.37 | 18.18 |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
